The Global Clinical Trial Imaging Market Size Is Worth USD 1.22 Billion in 2024 And is Estimated to Grow to USD 2.35 Billion By 2032, With a CAGR of Approximately 8.5 % Over the Forecast Period From 2024 To 2032.
The clinical trial imaging market refers to the sector that provides imaging services and technologies used during clinical trials to assess the efficacy and safety of new medical treatments, devices, and therapies. This market encompasses a range of imaging modalities, such as MRI, CT scans, PET scans, X-rays, and ultrasound, which are utilized to gather detailed information about a patient’s condition, monitor disease progression, and evaluate treatment responses.
Key components of the clinical trial imaging market include:
- Imaging Services: Companies and institutions that provide imaging services specifically for clinical trials.
- Imaging Technologies: Equipment and software used to capture and analyze imaging data.
- Regulatory Compliance: Ensuring that imaging practices adhere to regulatory standards and guidelines set by health authorities.
- Data Management: The handling and analysis of imaging data, including integration with clinical data.
- Outsourcing Trends: Many pharmaceutical and biotechnology companies outsource imaging services to specialized providers to streamline operations and ensure high-quality data collection.
The growth of this market is driven by increasing investments in research and development, the rise of personalized medicine, and the need for advanced imaging techniques to support innovative therapies.
Clinical trial imaging is an essential component of the drug development process, which helps in providing crucial information about the safety and efficacy of new drugs. The clinical trial imaging market is experiencing significant growth due to the increasing demand for innovative therapies and the growing need for accurate diagnosis and treatment evaluation.
Growth Drivers:
Several factors are driving the growth of the clinical trial imaging market, including the increasing prevalence of chronic diseases, rising healthcare expenditure, and the growing demand for personalized medicine. Additionally, the expanding number of clinical trials and the rising adoption of digital imaging technology are expected to boost the growth of the market.
Market Dynamics:
The clinical trial imaging market is highly competitive and is characterized by several established players. The market is also witnessing the emergence of several new players, which is intensifying the competition. Additionally, the market is highly regulated, which is expected to impact its growth of the market.
Recent Developments:
- The clinical trial imaging market is witnessing several recent developments, such as the introduction of new imaging techniques and the development of new drugs for the treatment of various diseases. Additionally, several companies are focusing on developing innovative imaging solutions to improve the accuracy of diagnosis and treatment evaluation.
Segmentation:
The Clinical Trial Imaging Market can be segmented based on Service, Application, and End-user.
- Service Insights: Based on Service, the market can be segmented into Clinical Trial Design and Consultation Services, Reading and Analytical Services, Operational Imaging Services, and others. Project and Data Management Services conquered the market with 30% of the market share in 2024. Clinical trials that utilize imaging typically require data management and workflow integration across several groups. These services incorporate operational expertise & trial workflow development, tracking projects, converting scans into digital images, regulatory control & quality assurance, real-time trial status reports, setup & management of MRI centers, data management, and reporting & issue resolution. The U.S. governance agreed on a cloud-based server that shields all the medical imaging records, such as annotated & base images, and secures reports from any natural disaster, and facilitates faster & easier retrieval.
- Application Insights: Based on Application, the market can be segmented into NASH, CKD, Diabetes, Cardiovascular Diseases, and Others. Nonalcoholic Steatohepatitis (NASH) is anticipated to expand at the quickest CAGR of 8.2% during the forecasted period. The growing burden of NASH due to the increasing prevalence of the disease is anticipated to propel segment expansion. Analyses suggest that the global prevalence of NASH is 25%, with the most elevated in the Middle East and South America and the lowest in Africa. Prevalence for the same is anticipated to rise to 62% by 2032, prompting the demand for its treatment. Consequently, to meet the need, organizations are concentrating on improving clinical trial analyses to assess the significance of treatments used for NASH.
- End-use Insights: Based on end-user, the market can be segmented into Biotechnology and Pharmaceutical companies, Medical Devices Manufacturers, Academic and Government Research Institutes, Contract Research Organizations (CROs), and Others. The Contract Research Organizations (CROs) segment accounted for the biggest share of 45.9% in 2022. This noteworthy market share can be attributed to the snowballing cost of drug development along with the advanced Research & Development activities.
Regional Insights:
North America conquered the global market with over 41.5% share of the global clinical trial imaging market in 2024. This can be attributed to the presence of large outsourcing companies and an expansion in R&D in the region. Various factors such as the increasing geriatric population along with increasing chronic diseases are anticipated to propel the market in North America. North America serves the most increased number of clinical trials. In addition, most outsourcing movements are from North America. Cost is another element donating to the outsourcing of clinical trials to other research associations.
Key Companies & Market Share Insights
- Some of the key players operating in the global clinical trial imaging market include
- IXICO plc
- Navitas Life Sciences
- Resonance Health
- ProScan Imaging
- Radiant Sage LLC
- Medpace
- Biomedical Systems Corp
- Cardiovascular Imaging Technologies
- Intrinsic Imaging
- BioTelemetry
Segments Covered in the Report
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Beyond Market Insights has segmented the global clinical trial imaging market based on service, application, end-user, and region:
Clinical Trial Imaging Market by Service Outlook (Revenue, USD Million, 2018 – 2032)
- Clinical Trial Design and Consultation Services
- Reading and Analytical Services
- Operational Imaging Services
- Computed Tomography (CT) ScanMRI (Magnetic Resonance Imaging)
- X-Ray
- Ultrasound
- Optical Coherence Tomography (OCT)
- Others
- System and Technology Support Services
- Project and Data Management
Clinical Trial Imaging Market by Modality Outlook (Revenue, USD Million, 2018 – 2032)
- Computed Tomography
- Magnetic Resonance Imaging
- X-Ray
- Ultrasound
- Optical Coherence Tomography (OCT)
- Others
Clinical Trial Imaging Market by Application Outlook (Revenue, USD Million, 2018 – 2032)
- NASH
- CKD
- Diabetes
- Cardiovascular Diseases
- Others
Clinical Trial Imaging Market by End-use Outlook (Revenue, USD Million, 2018 – 2032)
- Biotechnology and Pharmaceutical companies
- Medical devises Manufacturers
- Academic and Government Research Institutes
- Contract Research Organizations (CROs)
- Others
Clinical Trial Imaging Market by Regional Outlook (Revenue, USD Million, 2018 – 2032)
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Rest of Southeast Asia
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Clinical Trial Imaging Market Report Scope |
Report Attribute | Details |
| Market Size Value in 2024 | USD 1.22 billion |
| Revenue Forecast in 2032 | USD 2.35 billion |
| Growth Rate | CAGR of 8.5% from 2024 to 2032 |
| Base Year for Estimation | 2024 |
| Historical Data | 2018 – 2023 |
| Forecast Period | 2024 – 2032 |
| Quantitative Units | Revenue in USD million and CAGR from 2024 to 2032 |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered | Service, application, end-use, region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Country Scope | U.S.; Canada; U.K.; Germany; France; Italy; Spain; Japan; China; India; Thailand; South Korea; Brazil; Mexico; Colombia; Argentina; South Africa; Saudi Arabia; UAE |
| Key Companies Profiled | IXICO plc; Navitas Life Sciences; Resonance Health; ProScan Imaging; Radiant Sage LLC; Medpace; Biomedical Systems Corp; Cardiovascular Imaging Technologies; Intrinsic Imaging; BioTelemetry |
| |
TABLE OF CONTENT
Chapter 1. Clinical Trial Imaging Market: Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Service
1.1.2. Modality
1.1.3. Application
1.1.4. End Use
1.1.5. Regional scope
1.1.6. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Secondary sources
1.3.3. Primary research
1.3.4. Details of primary research
1.3.4.1. Data for Primary Interviews in North America
1.3.4.2. Data for primary interviews in Europe
1.3.4.3. Data for primary interviews in Asia Pacific
1.3.4.4. Data for Primary Interviews in Latin America
1.3.4.5. Data for Primary Interviews in MEA
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.2. Volume price analysis (Model 2)
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Clinical Trial Imaging Market: Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Service outlook
2.2.2. Modality outlook
2.2.3. Application outlook
2.2.4. End-use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Clinical Trial Imaging Market: Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Industry Value Chain Analysis
3.3.1. Reimbursement framework
3.4. Market Dynamics
3.4.1. Market Driver Analysis
3.4.1.1. Growing number of pharmaceutical and biotechnological companies
3.4.1.2. Growing number of contract research organizations (CRO)
3.4.1.3. Increasing research and development investments
3.4.2. Market Restraint Analysis
3.4.2.1. High cost of machinery and installations
3.5. X-ray Systems Market Analysis Tools
3.5.1. Industry Analysis – Porter’s
3.5.1.1. Supplier power
3.5.1.2. Buyer power
3.5.1.3. Substitution threat
3.5.1.4. Threat of new entrant
3.5.1.5. Competitive rivalry
3.5.2. PESTEL Analysis
3.5.2.1. Political landscape
3.5.2.2. Technological landscape
3.5.2.3. Economic Landscape
3.5.3. Major Deals & Strategic Alliances Analysis
3.5.4. Market Entry Strategies
Chapter 4. Clinical Trial Imaging Market: Service Estimates & Trend Analysis
4.1. Definitions and Scope
4.1.1. Clinical Trial Design and Consultation Services
4.1.2. Reading and Analytical Services
4.1.3. Operational Imaging
4.1.3.1. Computed Tomography (CT) Scan
4.1.3.2. MRI (Magnetic Resonance Imaging)
4.1.3.3. X-ray
4.1.3.4. Ultrasound
4.1.3.5. Optical Coherence Tomography (OCT)
4.1.3.6. Others
4.1.4. System and Technology Support Services
4.1.5. Project and Data Management
4.2. Services Market Share, 2018 & 2032
4.3. Segment Dashboard
4.4. Global Clinical Trial Imaging Market by Product Outlook
4.5. Market Size & Forecasts and Trend Analyses, 2018 to 2032 for the following
4.5.1. Clinical Trial Design and Consultation Services
4.5.1.1. Clinical Trial Design and Consultation Services market estimates and forecast 2018 to 2032 (USD Million)
4.5.2. Reading and Analytical Services
4.5.2.1. Reading and Analytical Services market estimates and forecast 2018 to 2032 (USD Million)
4.5.3. Operational Imaging Services
4.5.3.1. Operational Imaging Services market estimates and forecast 2018 to 2032 (USD Million)
4.5.4. System and Technology Support Services
4.5.4.1. System and Technology Support Services market estimates and forecast 2018 to 2032 (USD Million)
4.5.5. Project and Data Management
4.5.5.1. Project and Data Management market estimates and forecast 2018 to 2032 (USD Million)
Chapter 5. Clinical Trial Imaging Market: Modality Estimates & Trend Analysis
5.1. Definitions and Scope
5.1.1. Computed Tomography
5.1.2. Magnetic Resonance Imaging
5.1.3. X-Ray
5.1.4. Ultrasound
5.1.5. Optical Coherence Tomography (OCT)
5.1.6. Others
5.2. Modality Market Share, 2018& 2032
5.3. Segment Dashboard
5.4. Clinical Trial Imaging Market by Modality Outlook
5.5. Market Size & Forecasts and Trend Analyses, 2018 to 2032 for the following
5.5.1. Computed Tomography
5.5.1.1. Computed tomography estimates and forecast 2018 to 2032 (USD Million)
5.5.2. Magnetic Resonance Imaging
5.5.2.1. Magnetic resonance imaging estimates and forecast 2018 to 2032 (USD Million)
5.5.3. X-Ray
5.5.3.1. X-Ray market estimates and forecast 2018 to 2032 (USD Million)
5.5.4. Ultrasound
5.5.4.1. Ultrasound market estimates and forecast 2018 to 2032 (USD Million)
5.5.5. Optical Coherence Tomography (OCT)
5.5.5.1. Optical coherence tomography (OCT) market estimates and forecast 2018 to 2032 (USD Million)
5.5.6. Others
5.5.6.1. Others market estimates and forecast 2018 to 2032 (USD Million)
Chapter 6. Clinical Trial Imaging Market: Application Estimates & Trend Analysis
6.1. Definitions and Scope
6.1.1. Nonalcoholic Steatohepatitis (NASH)
6.1.2. Chronic Kidney Disease (CKD)
6.1.3. Diabetes
6.1.4. Cardiovascular Diseases
6.1.5. Ophthalmology
6.1.6. Musculoskeletal
6.1.7. Oncology
6.1.8. Gastroenterology
6.1.9. Pediatrics
6.1.10. Others
6.2. Application Market Share, 2018& 2032
6.3. Segment Dashboard
6.4. Clinical Trial Imaging Market by Application Outlook
6.5. Market Size & Forecasts and Trend Analyses, 2018 to 2032 for the following
6.5.1. Nonalcoholic Steatohepatitis (NASH)
6.5.1.1. Nonalcoholic steatohepatitis estimates and forecast 2018 to 2032 (USD Million)
6.5.2. Chronic Kidney Disease
6.5.2.1. Chronic kidney disease estimates and forecast 2018 to 2032 (USD Million)
6.5.3. Diabetes
6.5.3.1. Diabetes market estimates and forecast 2018 to 2032 (USD Million)
6.5.4. Cardiovascular Diseases
6.5.4.1. Cardiovascular diseases market estimates and forecast 2018 to 2032 (USD Million)
6.5.5. Ophthalmology
6.5.5.1. Ophthalmology market estimates and forecast 2018 to 2032 (USD Million)
6.5.6. Oncology
6.5.6.1. Oncology market estimates and forecast 2018 to 2032 (USD Million)
6.5.7. Musculoskeletal
6.5.7.1. Musculoskeletal market estimates and forecast 2018 to 2032 (USD Million)
6.5.8. Gastroenterology
6.5.8.1. Gastroenterology market estimates and forecast 2018 to 2032 (USD Million)
6.5.9. Pediatrics
6.5.9.1. Pediatrics market estimates and forecast 2018 to 2032 (USD Million)
6.5.10. Others
6.5.10.1. Others market estimates and forecast 2018 to 2032 (USD Million)
Chapter 7. Clinical Trial Imaging Market: End Use Estimates & Trend Analysis
7.1. Definitions and Scope
7.1.1. Biotechnology and Pharmaceutical Companies
7.1.2. Medical Devices Manufacturers
7.1.3. Academic and Government Research Institutes
7.1.4. Contract Research Organization (CRO)
7.1.5. Others
7.2. End Use Market Share, 2018 & 2032
7.3. Segment Dashboard
7.4. Clinical Trial Imaging Market by End-Use Outlook
7.5. Market Size & Forecasts and Trend Analyses, 2018 to 2032 for the following
7.5.1. Biotechnology and Pharmaceutical Companies
7.5.1.1. Biotechnology and pharmaceutical companies estimates and forecast 2018 to 2032 (USD Million)
7.5.2. Medical Devices Manufacturers
7.5.2.1. Medical devices Manufacturers estimates and forecast 2018 to 2032 (USD Million)
7.5.3. Academic and Government Research Institutes
7.5.3.1. Academic and government research institutes market estimates and forecast 2018 to 2032 (USD Million)
7.5.4. Contract Research Organization (CRO)
7.5.4.1. Contract research organization (CRO) market estimates and forecast 2018 to 2032 (USD Million)
7.5.5. Others
7.5.5.1. Others market estimates and forecast 2018 to 2032 (USD Million)
Chapter 8. Clinical Trial Imaging Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2023 & 2032
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2032:
8.5. North America
8.5.1. The U.S.
8.5.1.1. Key Country Dynamics
8.5.1.2. Regulatory framework/ reimbursement structure
8.5.1.3. Competitive scenario
8.5.1.4. U.S. market estimates and forecasts 2018 to 2032 (USD Million)
8.5.2. Canada
8.5.2.1. Key Country Dynamics
8.5.2.2. Regulatory framework/ reimbursement structure
8.5.2.3. Competitive scenario
8.5.2.4. Canada market estimates and forecasts 2018 to 2032 (USD Million)
8.6. Europe
8.6.1. UK
8.6.1.1. Key country dynamics
8.6.1.2. Regulatory framework/ reimbursement structure
8.6.1.3. Competitive scenario
8.6.1.4. UK market estimates and forecasts for 2018 to 2032 (USD Million)
8.6.2. Germany
8.6.2.1. Key Country Dynamics
8.6.2.2. Regulatory framework/ reimbursement structure
8.6.2.3. Competitive scenario
8.6.2.4. Germany market estimates and Forecasts 2018 to 2032 (USD Million)
8.6.3. France
8.6.3.1. Key Country Dynamics
8.6.3.2. Regulatory framework/ reimbursement structure
8.6.3.3. Competitive scenario
8.6.3.4. France market estimates and forecasts for 2018 to 2032 (USD Million)
8.6.4. Italy
8.6.4.1. Key Country Dynamics
8.6.4.2. Regulatory framework/ reimbursement structure
8.6.4.3. Competitive scenario
8.6.4.4. Italy market estimates and forecasts 2018 to 2032 (USD Million)
8.6.5. Spain
8.6.5.1. Key Country Dynamics
8.6.5.2. Regulatory framework/ reimbursement structure
8.6.5.3. Competitive scenario
8.6.5.4. Spain market estimates and forecasts for 2018 to 2032 (USD Million)
8.6.6. Norway
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework/ reimbursement structure
8.6.6.3. Competitive scenario
8.6.6.4. Norway market estimates and forecasts 2018 to 2032 (USD Million)
8.6.7. Sweden
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework/ reimbursement structure
8.6.7.3. Competitive scenario
8.6.7.4. Sweden market estimates and forecasts 2018 to 2032 (USD Million)
8.6.8. Denmark
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework/ reimbursement structure
8.6.8.3. Competitive scenario
8.6.8.4. Denmark market estimates and forecasts for 2018 to 2032 (USD Million)
8.7. Asia Pacific
8.7.1. Japan
8.7.1.1. Key country dynamics
8.7.1.2. Regulatory framework/ reimbursement structure
8.7.1.3. Competitive scenario
8.7.1.4. Japan market estimates and forecasts 2018 to 2032 (USD Million)
8.7.2. China
8.7.2.1. Key Country Dynamics
8.7.2.2. Regulatory framework/ reimbursement structure
8.7.2.3. Competitive scenario
8.7.2.4. China market estimates and forecasts 2018 to 2032 (USD Million)
8.7.3. India
8.7.3.1. Key Country Dynamics
8.7.3.2. Regulatory framework/ reimbursement structure
8.7.3.3. Competitive scenario
8.7.3.4. India market estimates and forecasts 2018 to 2032 (USD Million)
8.7.4. Australia
8.7.4.1. Key Country Dynamics
8.7.4.2. Regulatory framework/ reimbursement structure
8.7.4.3. Competitive scenario
8.7.4.4. Australia market estimates and forecasts 2018 to 2032 (USD Million)
8.7.5. South Korea
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ reimbursement structure
8.7.5.3. Competitive scenario
8.7.5.4. South Korea market estimates and forecasts 2018 to 2032 (USD Million)
8.7.6. Thailand
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ reimbursement structure
8.7.6.3. Competitive scenario
8.7.6.4. Thailand market estimates and forecasts 2018 to 2032 (USD Million)
8.8. Latin America
8.8.1. Brazil
8.8.1.1. Key country dynamics
8.8.1.2. Regulatory framework/ reimbursement structure
8.8.1.3. Competitive scenario
8.8.1.4. Brazil market estimates and forecasts for 2018 to 2032 (USD Million)
8.8.2. Mexico
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework/ reimbursement structure
8.8.2.3. Competitive scenario
8.8.2.4. Mexico market estimates and forecasts 2018 to 2032 (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ reimbursement structure
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts for 2018 to 2032 (USD Million)
8.9. MEA
8.9.1. South Africa
8.9.1.1. Key country dynamics
8.9.1.2. Regulatory framework/ reimbursement structure
8.9.1.3. Competitive scenario
8.9.1.4. South Africa market estimates and forecasts 2018 to 2032 (USD Million)
8.9.2. Saudi Arabia
8.9.2.1. Key Country Dynamics
8.9.2.2. Regulatory framework/ reimbursement structure
8.9.2.3. Competitive scenario
8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2032 (USD Million)
8.9.3. UAE
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ reimbursement structure
8.9.3.3. Competitive scenario
8.9.3.4. UAE market estimates and forecasts 2018 to 2032 (USD Million)
8.9.4. Kuwait
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ reimbursement structure
8.9.4.3. Competitive scenario
8.9.4.4. Kuwait market estimates and forecasts for 2018 to 2032 (USD Million)
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.2.1. Innovators
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. IXICO plc
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Product benchmarking
9.3.4.4. Strategic initiatives
9.3.5. Navitas Life Sciences
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Product benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Resonance Health
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Product benchmarking
9.3.6.4. Strategic initiatives
9.3.7. ProScan Imaging
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Product benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Radiant Sage LLC
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Product benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Medpace
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Product benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Biomedical Systems Corp.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Product benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Cardiovascular Imaging Technologies
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Product benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Intrinsic Imaging
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Product benchmarking
9.3.12.4. Strategic initiatives
9.3.13. BioTelemetry
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Product benchmarking
9.3.13.4. Strategic initiatives
Clinical Trial Imaging Market by Service Outlook (Revenue, USD Million, 2018 – 2032)
- Clinical Trial Design and Consultation ServicesReading and Analytical Services
- Operational Imaging Services
- Computed Tomography (CT) ScanMRI (Magnetic Resonance Imaging)
- X-Ray
- Ultrasound
- Optical Coherence Tomography (OCT)
- Others
- System and Technology Support Services
- Project and Data Management
Clinical Trial Imaging Market by Modality Outlook (Revenue, USD Million, 2018 – 2032)
- Computed Tomography
- Magnetic Resonance Imaging
- X-Ray
- Ultrasound
- Optical Coherence Tomography (OCT)
- Others
Clinical Trial Imaging Market by Application Outlook (Revenue, USD Million, 2018 – 2032)
- NASH
- CKD
- Diabetes
- Cardiovascular Diseases
- Others
Clinical Trial Imaging Market by End-use Outlook (Revenue, USD Million, 2018 – 2032)
- Biotechnology and Pharmaceutical companies
- Medical devises Manufacturers
- Academic and Government Research Institutes
- Contract Research Organizations (CROs)
- Others
Clinical Trial Imaging Market by Regional Outlook (Revenue, USD Million, 2018 – 2032)
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Rest of Southeast Asia
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
